Clinical Trials Browser

INDUSTRY × fludarabine × Sarcoma × Clear all

NCT03967223 2026-02-25

IGNYTE-ESO

Phase 2 Active not recruiting

Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT07174427 2026-02-18

Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

Phase 3 Recruiting

Sarcoma, Synovial

NCT04526509 2024-11-26

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Phase 1 Terminated

12 enrolled 12 charts

Neoplasms, Liposarcoma, Myxoid

NCT05943990 2024-11-13

Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase 1 Terminated

5 enrolled 16 charts

Neoplasms, Liposarcoma, Myxoid

NCT04282044 2024-02-08

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

Phase 1 Recruiting

BreastDermatologicGastrointestinalGynecologicSarcomaThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Osteosarcoma, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02992743 2023-04-11

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

Phase 2 Completed

23 enrolled 25 charts

Neoplasms, Liposarcoma, Myxoid

NCT01343043 2021-06-30

NY-ESO-1

Phase 1 Completed

50 enrolled 17 charts

Neoplasm Metastasis, Neoplasms, Sarcoma

NCT03697824 2019-10-29

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Phase 2 Withdrawn

Neoplasms, Sarcoma, Synovial